Travere Therapeutics (NASDAQ:TVTX) Issues Earnings Results, Misses Estimates By $0.15 EPS

Travere Therapeutics (NASDAQ:TVTX) posted its quarterly earnings results on Thursday. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.15), Zacks reports. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%.

Travere Therapeutics Trading Up 1.1 %

NASDAQ TVTX traded up $0.25 during trading on Thursday, hitting $23.58. The stock had a trading volume of 1,320,310 shares, compared to its average volume of 1,582,407. Travere Therapeutics has a one year low of $5.12 and a one year high of $25.29. The stock has a 50 day simple moving average of $19.47 and a 200 day simple moving average of $16.43. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of -5.18 and a beta of 0.72. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71.

Insider Activity

In related news, CAO Sandra Calvin sold 54,244 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total value of $1,356,100.00. Following the transaction, the chief accounting officer now owns 54,410 shares of the company’s stock, valued at $1,360,250. This trade represents a 49.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Eric M. Dube sold 11,375 shares of Travere Therapeutics stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $24.04, for a total transaction of $273,455.00. Following the sale, the chief executive officer now owns 419,173 shares of the company’s stock, valued at $10,076,918.92. The trade was a 2.64 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 218,425 shares of company stock valued at $4,674,259. 3.75% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts have issued reports on TVTX shares. Scotiabank lifted their price target on shares of Travere Therapeutics from $27.00 to $32.00 and gave the company a “sector outperform” rating in a report on Wednesday, February 12th. Canaccord Genuity Group lifted their target price on Travere Therapeutics from $22.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, February 12th. Barclays increased their price target on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Cantor Fitzgerald started coverage on Travere Therapeutics in a report on Friday, January 10th. They set an “overweight” rating on the stock. Finally, HC Wainwright raised their target price on shares of Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, January 15th. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, Travere Therapeutics has an average rating of “Moderate Buy” and an average price target of $27.77.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.